SG11202109997PA - Novel azaindole derivative - Google Patents

Novel azaindole derivative

Info

Publication number
SG11202109997PA
SG11202109997PA SG11202109997PA SG11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA
Authority
SG
Singapore
Prior art keywords
azaindole derivative
novel azaindole
novel
derivative
azaindole
Prior art date
Application number
Other languages
English (en)
Inventor
Gen Watanabe
Toshiharu Morimoto
Akira Iwata
Hirotaka Sasaki
Takahisa Ogamino
Kosuke Usuda
Ayumu Okuda
Hiroyuki Ishiwata
Yuichiro Tabunoki
Keigo Nishii
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of SG11202109997PA publication Critical patent/SG11202109997PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202109997P 2019-03-29 2020-03-30 Novel azaindole derivative SG11202109997PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068233 2019-03-29
PCT/JP2020/014475 WO2020203950A1 (ja) 2019-03-29 2020-03-30 新規アザインドール誘導体

Publications (1)

Publication Number Publication Date
SG11202109997PA true SG11202109997PA (en) 2021-10-28

Family

ID=72668977

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109997P SG11202109997PA (en) 2019-03-29 2020-03-30 Novel azaindole derivative

Country Status (10)

Country Link
US (1) US20220162206A1 (de)
EP (1) EP3950063A4 (de)
JP (1) JPWO2020203950A1 (de)
KR (1) KR20210146320A (de)
CN (1) CN113613729A (de)
BR (1) BR112021019050A2 (de)
CA (1) CA3134937A1 (de)
MX (1) MX2021011923A (de)
SG (1) SG11202109997PA (de)
WO (1) WO2020203950A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288918A (en) * 1992-09-29 1994-02-22 Union Carbide Chemicals & Plastics Technology Corporation Hydroformylation process
US5767321A (en) * 1995-12-06 1998-06-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
PT1696920E (pt) 2003-12-19 2015-01-14 Plexxikon Inc Compostos e métodos para o desenvolvimento de moduladores de ret
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CN107074882B (zh) * 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的吡唑并嘧啶衍生物
BR112018001017B1 (pt) * 2015-07-20 2024-02-15 Genzyme Corporation Inibidores do receptor de fator-1 de estimulação de colônia (csf-1r), composição farmacêutica e seu uso
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors

Also Published As

Publication number Publication date
EP3950063A1 (de) 2022-02-09
JPWO2020203950A1 (de) 2020-10-08
BR112021019050A2 (pt) 2021-11-30
EP3950063A4 (de) 2022-11-30
CN113613729A (zh) 2021-11-05
CA3134937A1 (en) 2020-10-08
WO2020203950A1 (ja) 2020-10-08
US20220162206A1 (en) 2022-05-26
KR20210146320A (ko) 2021-12-03
MX2021011923A (es) 2021-11-03

Similar Documents

Publication Publication Date Title
IL286846A (en) History of camptothecin
IL275365A (en) 6-Azaindole compounds
GB202201999D0 (en) Interleukin-2 Derivative
ZA202204675B (en) New methylquinazolinone derivatives
IL289197A (en) History of 2-hydroxycycloalkane-1-carbamoyl
IL290964A (en) A 2-aminoquinazolinone derivative
IL289589A (en) New methods
EP3406612A4 (de) Carbolinderivat als bromodomäneninhibitor
IL279938A (en) History of spirochroman
IL290815A (en) History of alpha-d-galactopyranoside
LT3796975T (lt) Sulfonilaminobenzamido dariniai
IL288950A (en) History of pyridine-3-yl
EP4039331A4 (de) Azepinderivate
SG11202007979UA (en) Dihydrochromene derivative
EP3885347A4 (de) Dihydropyrrolopyrazol-derivat
SG11202006837XA (en) Dihydroindolizinone derivative
SG11202109997PA (en) Novel azaindole derivative
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
GB201911762D0 (en) Novel methods
GB201911764D0 (en) Novel Methods
GB201919213D0 (en) Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
EP3872061A4 (de) 1-phenyl-2-phenylethanderivate
EP4062972A4 (de) Pyrazolomorphinanderivate
GB201917413D0 (en) Zeolite
GB201901043D0 (en) Novel methods